|
GHS and its clients are seeing an acceleration of strong M/A activity in diagnostics, as we have predicted. As the clinical utility of diagnostics increases due to new science; as the new science enables new players to enter health care (especially in prevention and the treatment of chronic disease); as pharma’s offerings are increasingly targeted by companion diagnostics – the range and value of diagnostic companies and diagnostic intellectual property is soaring.
We believe that there are opportunities in this space for equity investors with vision and understanding of the space. (See Batchelder & Miller, “A change in the markets – investing in diagnostics”, Nature Biotechnology, August 2006.)
Genomic Healthcare Strategies has worked in strategy development, the selecting, vetting, and acquisition of diagnostic companies and IP in order to create strong focused companies around particular prevention and disease areas.
Genomic Healthcare Strategies will:
- Manage the acquisition of diagnostic companies and IP
- Actively participate in targeted diagnostic roll-ups
- Provide consulting services to support the accumulation of diagnostic companies and IP properties:
- Strategy formulation and acquisition criteria development
- Strategy and business plan review
- Search coordination
- Candidate due diligence
- Post-acquisition management support
We work with multiple equity sources simultaneously so long as their areas of interest do not overlap.
|
